Relmada Therapeutics, Inc.
RLMD
Rank in Stocks
#12760
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Share Price
$4.14
Last synced: 2026-11-09
Market Cap
$441.61M
Change (1 day)
6.15%
Change (1 year)
5.88%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Relmada Therapeutics, Inc. (RLMD)
Category
Healthcare
EPS for Relmada Therapeutics, Inc. (RLMD)
EPS as of June 2026 TTM: $-0.92
According to Relmada Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.92. At the end of 2025 the company had an EPS of $-1.45, an increase over its 2024 EPS of $-2.65.
EPS history for Relmada Therapeutics, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.92 | -36.55% |
| 2025 | $-1.45 | -45.28% |
| 2024 | $-2.65 | -19.21% |
| 2023 | $-3.28 | -38.11% |
| 2022 | $-5.30 | -25.98% |
| 2021 | $-7.16 | 87.93% |
| 2020 | $-3.81 | 133.74% |
| 2019 | $-1.63 | -43.01% |
| 2018 | $-2.86 | 37.50% |
| 2017 | $-2.08 | 101.94% |
| 2016 | $-1.03 | -87.69% |
| 2015 | $-8.37 | 26,387.34% |
| 2013 | $-0.03 | 271.76% |
| 2012 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,802.17% |
US
|
|
| $-7.07 | 668.48% |
US
|
|
| $-5.29 | 475.00% |
AU
|
|
| $12.88 | -1,500.01% |
BE
|
|
| $21.56 | -2,443.48% |
NL
|
Questions about Relmada Therapeutics, Inc.'s earnings per share (EPS)
What is Relmada Therapeutics, Inc.'s earnings per share (EPS)?
Relmada Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.92, as of Jun 2026.
What was Relmada Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Relmada Therapeutics, Inc.'s earnings per share (EPS) was $-1.45, compared with $-2.65 in 2024.
How has Relmada Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Relmada Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.45) and lowest in 2021 ($-7.16).
How does Relmada Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Relmada Therapeutics, Inc.'s earnings per share (EPS) ($-0.92) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.